JIP-1 (A99) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
JIP-1 (A99) Peptide Applications :
Blocking Background :
Two additional JNK family members have been identified as JNK2 and JNK3. JIP-1 (for JNK interacting protein-1) has been identified as a cytoplasmic inhibitor of JNK that retains JNK in the cytoplasm, thereby inhibiting JNK-regulated gene expression. Evidence suggests that JNK1 and JNK2 bind to JIP-1 with greater affinity than to ATF-2 and c-Jun, which are targets of the JNK signaling pathway. JIP-1 contains an amino terminal JNK binding domain and a carboxy terminal SH3 domain. ATF-2 and c-Jun also contain the JNK binding domain and are thought to compete with JIP-1 for JNK binding. Multiple splice variants of JIP-1, including JIP-1b, JIP-1c (also designated islet-brain 1 or IB-1), JIP-2a, JIP-2b and JIP-3, have been identified in brain. Alternative Name :
C jun amino terminal kinase interacting protein 1; IB 1; IB1; Islet brain 1; JIP 1; JNK interacting protein 1; JNK MAP kinase scaffold protein 1; MAPK8IP 1; MAPK8IP1; MAPK8IP1 mitogen-activated protein kinase 8 interacting protein 1; Mitogen activated protein kinase 8 interacting protein 1; PRKM8; PRKM8 interacting protein; PRKM8IP Swiss-Prot :
Q9UQF2 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide JIP-1 (A99). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS9237 JIP-1 (A99) pAb.
JIP-1 (A99) Peptide Applications :
Blocking Background :
Two additional JNK family members have been identified as JNK2 and JNK3. JIP-1 (for JNK interacting protein-1) has been identified as a cytoplasmic inhibitor of JNK that retains JNK in the cytoplasm, thereby inhibiting JNK-regulated gene expression. Evidence suggests that JNK1 and JNK2 bind to JIP-1 with greater affinity than to ATF-2 and c-Jun, which are targets of the JNK signaling pathway. JIP-1 contains an amino terminal JNK binding domain and a carboxy terminal SH3 domain. ATF-2 and c-Jun also contain the JNK binding domain and are thought to compete with JIP-1 for JNK binding. Multiple splice variants of JIP-1, including JIP-1b, JIP-1c (also designated islet-brain 1 or IB-1), JIP-2a, JIP-2b and JIP-3, have been identified in brain. Alternative Name :
C jun amino terminal kinase interacting protein 1; IB 1; IB1; Islet brain 1; JIP 1; JNK interacting protein 1; JNK MAP kinase scaffold protein 1; MAPK8IP 1; MAPK8IP1; MAPK8IP1 mitogen-activated protein kinase 8 interacting protein 1; Mitogen activated protein kinase 8 interacting protein 1; PRKM8; PRKM8 interacting protein; PRKM8IP Swiss-Prot :
Q9UQF2 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide JIP-1 (A99). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS9237 JIP-1 (A99) pAb.
Blocking peptide available as BS9237PP